SIGA Technologies Inc. is a high-risk pharmaceutical company in the United States, with an ESG score of 31.6. Specializing in the health security market, SIGA Technologies Inc. primarily generates revenue from its main product, TPOXX, an oral antiviral drug for smallpox treatment.